Join in the healthcare conversation on SIRIUSXM Channel 111 - the Wharton business channel! A panel of experts will discuss the future of regenerative medicine.
Our next radio session, The Future of Regenerative Medicine, will be Tuesday, February 9th from 12:00pm to 1:00pm EST.
Regenerative medicine is a new and expanding area that aims to replace lost or damaged tissues in the human body through either cellular transplantation or endogenous repair. This field has sales in excess of $18 billion and is expected to grow at a 23% compound annual growth rate over the next 4-5 years. Hear from experts in 3 areas of tissue regeneration – kidney, heart, and appendages how these types of tissues are being developed and what some of the hurdles are for growing this market.
Click here to register. Open only to current dues-paying members of WHCMAA. Available to 50 participants.
The user name and password for access to this session will be emailed to all participants on Monday, February 8th.
Susan Quaggin, MD graduated from the Faculty of Medicine at the University of Toronto in 1988 and received her specialty degree in Internal Medicine in 1992. She completed her sub-specialty training in Nephrology in 1993 at U of T and did a post-doctoral fellowship at Yale University where she studied the genetic basis of kidney development. In January 2013, Quaggin joined Northwestern University Feinberg School of Medicine as the Charles Horace Mayo Professor of Medicine, where she serves as the director of the Feinberg Cardiovascular Research Institute (FCVRI) and chief of the Division of Nephrology.
Quaggin's research program focuses on genetic pathways required to establish and maintain the integrity of microvascular beds including the glomerular filtration barrier – a highly selective filter that separates the blood from the urinary space. To understand the pathways and interactions between perivascular cells and the endothelium, her research team has developed a number of genetic models that permit cell and time-specific manipulation of gene expression.
Peter A. Altman, Ph.D. has served as Biocardia’s President and Chief Executive Officer since 2002, where he has global responsibility for the development, manufacture and marketing of our therapeutic candidates and products. He was founding Chief Executive Officer from 1999 to 2003 and board member of CareDx, a developer of a gene based diagnostics to be used in chronic inflammatory diseases, including cardiac transplantation, coronary artery disease and systemic lupus erythematosus. He was also founding Chief Executive Officer for Lumen Therapeutics from 2004 to 2005, an early-stage pharmaceutical company. He received his Ph.D. in Bioengineering/Pharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his Master of Science and Bachelor of Science in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman has been elected Fellow of the American Heart Association. He has over 27 years of experience in life science research and product development, is named inventor in 40 U.S. patents, and has authored 38 scientific publications in cardiology, ophthalmology and spine.
Thomas Leung, MD, PhD. After college at Stanford, Thomas went to UCLA and Caltech for his MD and PhD degrees. As a graduate student, he worked with Nobelist David Baltimore studying gene regulation. He returned to Stanford for his medical residency in Dermatology and trained with Seung Kim studying developmental biology. In 2015, he moved to the University of Pennsylvania. His lab seeks to improve our understanding of mammalian tissue regeneration and to develop novel therapeutics for regenerative medicine.
Jeffrey Voigt, WG’85. Principal of Medical Device Consultants of Ridgewood, LLC, a firm dedicated to helping early stage medical technology companies with reimbursement with a focus on identifying value through cost-effectiveness analysis. Jeff is a regular host of The Business of Healthcare on SIRIUSXM 111, powered by the Wharton School.
Friday, February 12th at 9:00 am EST
Saturday, February 13th at 4:00 pm EST
Sunday, February 14th at 9:00 pm EST
Note: If we become oversubscribed to this offer, our goal will be to extend the one hour radio segment to 2 hours (to ensure your voice is heard). Lastly, if you have an idea for a panel discussion or would like to be a panelist for a session, please email Jeff Voigt at email@example.com. Again, this is open only to dues paying members.
Please visit our Events page for a listing of additional sessions: http://www.whartonhealthcare.org/events.html.